<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3772">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565249</url>
  </required_header>
  <id_info>
    <org_study_id>PLN-74809-ARDS-204</org_study_id>
    <nct_id>NCT04565249</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19</brief_title>
  <official_title>A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pliant Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pliant Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants&#xD;
      with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 36 participants will be enrolled sequentially into 3 cohorts. Within each&#xD;
      cohort of 12 participants, 9 will be randomized to PLN-74809 and 3 will be randomized to&#xD;
      placebo (3:1 ratio).&#xD;
&#xD;
        -  In Part 1, approximately 12 participants will be randomized to Dose level 1 of PLN-74809&#xD;
           or placebo QD&#xD;
&#xD;
        -  In Part 2, approximately 12 participants will be randomized to Dose level 2 of PLN-74809&#xD;
           or placebo QD&#xD;
&#xD;
        -  In Part 3, approximately 12 participants will be randomized to Dose level 3 of PLN-74809&#xD;
           or placebo QD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events and laboratory abnormalities, assessed by CTCAE V5.0</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PLN-74809 plasma concentrations</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants alive and free of invasive mechanical ventilation</measure>
    <time_frame>up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants alive and discharged from hospital</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants alive and discharged from hospital</measure>
    <time_frame>Up to 90 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>PLN-74809 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1 of PLN-74809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2 of PLN-74809</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLN-74809 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 3 of PLN-74809</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLN-74809</intervention_name>
    <description>PLN-74809</description>
    <arm_group_label>PLN-74809 Dose 1</arm_group_label>
    <arm_group_label>PLN-74809 Dose 2</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>PLN-74809 Dose 1</arm_group_label>
    <arm_group_label>PLN-74809 Dose 2</arm_group_label>
    <arm_group_label>PLN-74809 Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ARDS (Berlin Criteria)&#xD;
&#xD;
          -  Hospitalized with at least severe COVID-19 (FDA 2020)&#xD;
&#xD;
          -  Receiving support for acute lung injury/respiratory distress via supplemental oxygen&#xD;
&#xD;
          -  Serum aspartate aminotransferase (AST) concentration ≤ 120 U/L and serum alanine&#xD;
             aminotransferase (ALT) concentration ≤ 150 U/L&#xD;
&#xD;
          -  Serum total bilirubin ≤ 1.8 mg/dL, in the absence of Gilbert's syndrome or hemolysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Greater than 72 hours since time of onset of ARDS.&#xD;
&#xD;
          -  Greater than 7 days since start of mechanical ventilation.&#xD;
&#xD;
          -  Currently receiving or anticipated to receive extracorporeal life support (ECLS),&#xD;
             extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation&#xD;
&#xD;
          -  Unwillingness to follow lung protective ventilation strategy (i.e., tidal volume of 6&#xD;
             mL/kg of predicted body weight and prone positioning) and fluid management protocol&#xD;
             (Fluids and Catheters Treatment Trial [FACTT] Conservative or Lite) per local&#xD;
             institutional standards (HFOV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pliant Therapeutics</last_name>
    <role>Study Director</role>
    <affiliation>Pliant Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pliant Therapeutics Medical Monitor</last_name>
    <phone>clintrials@pliantrx.com</phone>
    <email>clintrials@pliantrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valleywise Health Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rania Rahman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rania Rahman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Janssen, MD</last_name>
    </contact>
    <investigator>
      <last_name>William Janssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amay Parikh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amay Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

